Boston Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in serious liver diseases, has appointed Dr. Margaret Koziel as its Chief Medical Officer (CMO). Dr. Koziel’s appointment marks a significant milestone for the company as it continues to advance its lead program, BOS-580, aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH).
Dr. Koziel brings with her a wealth of experience in drug development and executive leadership, spanning over 16 years. Prior to joining Boston Pharmaceuticals, she held CMO positions at Innoviva Specialty Therapeutics, Inc. and Axcella Therapeutics, Inc., where she played a pivotal role in advancing programs focused on liver diseases, including MASH. Her extensive background also includes positions at Kaleido Biosciences, Vertex, and the Novartis Institute for Biomedical Sciences, where she contributed to drug development across various therapeutic areas, including hepatology, infectious diseases, oncology, rare diseases, long COVID, and immunology.
In addition to her industry experience, Dr. Koziel has held academic positions at the University of Massachusetts Medical School and Harvard Medical School, where her research focused on hepatitis C virus and HIV. She is a prolific author, with over 90 publications in prestigious journals, such as the New England Journal of Medicine and Journal of Clinical Investigation.
Dr. Koziel’s appointment comes at a crucial time for Boston Pharmaceuticals as it progresses its lead candidate, BOS-580, through late-stage clinical development. The company is anticipating biopsy results soon for patients with stage F2 and F3 disease, and Dr. Koziel’s expertise in liver diseases will be invaluable in achieving further developmental milestones.
Boston Pharmaceuticals is poised to leverage Dr. Koziel’s leadership and expertise as it continues to advance its portfolio of therapies aimed at addressing unmet medical needs in serious liver diseases, with a focus on MASH. Dr. Koziel’s appointment underscores the company’s commitment to delivering innovative treatments to patients in need.
